All treatments
Treatment
Aybintio 25 mg/ml concentrate for solution for infusion. clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER
This study is testing a new drug, Ezurpimtrostat, alongside standard treatments (Atezolizumab and Bevacizumab) for advanced liver cancer that can't be removed by surgery. It aims to see how well this new combination stops the cancer from growing.
For: unresectable hepatocellular carcinomaFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
This study looks at a new drug, DKN-01, combined with standard treatments for advanced bowel cancer. It compares this new combination to the standard treatments alone, to see if it helps people live longer without their cancer growing.
For: Colorectal CancerGermany